Patient characteristics according to GVHD treatment group and for non-GVHD controls
| . | Non-GVHD controls n = 191 . | Steroids alone n = 99 . | Etanercept plus steroids n = 61 . | P for difference between 2 treatment groups . |
|---|---|---|---|---|
| Median age, y (range) | 44 (1-69) | 49 (1-71) | 51 (7-65) | .77 |
| Patients < 18 y, % | 15 | 9 | 10 | .88 |
| Myeloablative conditioning, % | 77 | 68 | 61 | .37 |
| Unrelated donor, % | 32 | 46 | 31 | .06 |
| Mismatched, % | 6 | 16 | 11 | .60 |
| Advanced malignancy, %* | 22 | 25 | 31 | .42 |
| Nonmalignant disease, % | 6 | 1 | 0 | .43 |
| GVHD at start of treatment, % | ||||
| Grade 2 | — | 69 | 67 | .84 |
| Grades 3-4 | — | 31 | 33 | |
| Skin | — | 69 | 61 | .60 |
| Skin only target organ | 49 | 34 | .08 | |
| Liver | — | 15 | 15 | .47 |
| GI tract | — | 44 | 61 | .16 |
| Upper GI only target organ | — | 5 | 3 | .60 |
| . | Non-GVHD controls n = 191 . | Steroids alone n = 99 . | Etanercept plus steroids n = 61 . | P for difference between 2 treatment groups . |
|---|---|---|---|---|
| Median age, y (range) | 44 (1-69) | 49 (1-71) | 51 (7-65) | .77 |
| Patients < 18 y, % | 15 | 9 | 10 | .88 |
| Myeloablative conditioning, % | 77 | 68 | 61 | .37 |
| Unrelated donor, % | 32 | 46 | 31 | .06 |
| Mismatched, % | 6 | 16 | 11 | .60 |
| Advanced malignancy, %* | 22 | 25 | 31 | .42 |
| Nonmalignant disease, % | 6 | 1 | 0 | .43 |
| GVHD at start of treatment, % | ||||
| Grade 2 | — | 69 | 67 | .84 |
| Grades 3-4 | — | 31 | 33 | |
| Skin | — | 69 | 61 | .60 |
| Skin only target organ | 49 | 34 | .08 | |
| Liver | — | 15 | 15 | .47 |
| GI tract | — | 44 | 61 | .16 |
| Upper GI only target organ | — | 5 | 3 | .60 |
GI indicates gastrointestinal; and —, not applicable.
Chronic myelogenous leukemia in chronic phase, myelodysplastic syndrome, multiple myeloma, acute leukemia in CR, and lymphoma in partial response (PR) or CR were considered nonadvanced disease for the purposes of analysis. Leukemia or lymphoma in untreated relapse or refractory to therapy were considered advanced disease for the purposes of analysis.